At Touchlight we are revolutionising DNA. Our Company and technology is built on the conviction that DNA is fundamental to the future of medicine. By moving away from today's restrictive biological approaches, we have made DNA simple. Our unique dbDNA™ (or "doggybone" DNA) vector is optimised for use in advanced genetic medicines, being safer and more efficacious than conventional plasmid DNA. The platform, based on enzymatic technology, enable DNA production at unprecedented scale, speed and purity. We are leveraging our platform to develop the next generation of DNA vaccines for oncology and infectious diseases, in house and in collaboration with industry partners and academics, as well as enabling manufacture of advanced therapies (viral vectors, mRNA vaccines, and cell therapies) through our CDMO, Touchlight DNA Services.